Sagberg Lisa Millgård, Jakola Asgeir S, Solheim Ole
Department of Neuroscience, Norwegian University of Science and Technology, 7491, Trondheim, Norway,
Qual Life Res. 2014 Jun;23(5):1427-34. doi: 10.1007/s11136-013-0593-4. Epub 2013 Dec 7.
To evaluate the responsiveness of EQ-5D 3L in patients undergoing intracranial glioma surgery and estimate the minimal clinically important difference (MCID).
EQ-5D 3L index values from 164 patients who underwent glioma surgery in the period 2007-2012 were analysed. Responsiveness and MCID were estimated using a combination of distribution-based and anchor-based methods. Karnofsky performance status served as an anchor.
Patients who improved functionally did not report significantly higher EQ-5D 3L scores post operatively with a standardized response mean (SRM) of 0.04 (p = 0.13). Patients who deteriorated functionally reported significantly lower EQ-5D 3L scores post operatively with a SRM of 0.72 (p < 0.001). With different approaches, we determined a range of MCID values from 0.13 to 0.15.
EQ-5D 3L is responsive to changes when glioma patients are deteriorating functionally after surgery but not responsive when the patients are improving. The MCID values for EQ-5D 3L in glioma surgery seem higher than reported MCID values for other types of cancers.
评估EQ-5D 3L对颅内胶质瘤手术患者的反应性，并估计最小临床重要差异（MCID）。
分析了2007年至2012年期间接受胶质瘤手术的164例患者的EQ-5D 3L指数值。使用基于分布和基于锚定的方法相结合来估计反应性和MCID。卡诺夫斯基功能状态作为一个锚定指标。
功能改善的患者术后EQ-5D 3L评分无显著升高，标准化反应均值（SRM）为0.04（p = 0.13）。功能恶化的患者术后EQ-5D 3L评分显著降低，SRM为0.72（p < 0.001）。通过不同方法，我们确定的MCID值范围为0.13至0.15。
当胶质瘤患者术后功能恶化时，EQ-5D 3L对变化有反应，但当患者功能改善时则无反应。胶质瘤手术中EQ-5D 3L的MCID值似乎高于其他类型癌症报告的MCID值。
